دورية أكاديمية
أعرض في EDS

Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo.

التفاصيل البيبلوغرافية
العنوان: Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo.
المؤلفون: Antillon M; Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Basel, 4123, Switzerland. marina.antillon@swisstph.ch.; University of Basel, Basel, 4001, Switzerland. marina.antillon@swisstph.ch., Huang CI; Zeeman Institute, University of Warwick, Coventry, CV4 7AL, UK.; Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK., Crump RE; Zeeman Institute, University of Warwick, Coventry, CV4 7AL, UK.; Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK., Brown PE; Zeeman Institute, University of Warwick, Coventry, CV4 7AL, UK.; Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK., Snijders R; Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Basel, 4123, Switzerland.; University of Basel, Basel, 4001, Switzerland.; Institute of Tropical Medicine, B-2000 Antwerp, Belgium., Miaka EM; Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of Congo., Keeling MJ; Zeeman Institute, University of Warwick, Coventry, CV4 7AL, UK.; Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK.; School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK., Rock KS; Zeeman Institute, University of Warwick, Coventry, CV4 7AL, UK. k.s.rock@warwick.ac.uk.; Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK. k.s.rock@warwick.ac.uk., Tediosi F; Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Basel, 4123, Switzerland.; University of Basel, Basel, 4001, Switzerland.
المصدر: Nature communications [Nat Commun] 2022 Feb 25; Vol. 13 (1), pp. 1051. Date of Electronic Publication: 2022 Feb 25.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Trypanosomiasis, African*/epidemiology , Trypanosomiasis, African*/prevention & control, Animals ; Cost-Benefit Analysis ; Democratic Republic of the Congo/epidemiology ; Humans ; Mass Screening ; Trypanosoma brucei gambiense
مستخلص: Gambiense human African trypanosomiasis (gHAT) is marked for elimination of transmission by 2030, but the disease persists in several low-income countries. We couple transmission and health outcomes models to examine the cost-effectiveness of four gHAT elimination strategies in five settings - spanning low- to high-risk - of the Democratic Republic of Congo. Alongside passive screening in fixed health facilities, the strategies include active screening at average or intensified coverage levels, alone or with vector control with a scale-back algorithm when no cases are reported for three consecutive years. In high or moderate-risk settings, costs of gHAT strategies are primarily driven by active screening and, if used, vector control. Due to the cessation of active screening and vector control, most investments (75-80%) are made by 2030 and vector control might be cost-saving while ensuring elimination of transmission. In low-risk settings, costs are driven by passive screening, and minimum-cost strategies consisting of active screening and passive screening lead to elimination of transmission by 2030 with high probability.
(© 2022. The Author(s).)
References: PLoS Negl Trop Dis. 2020 Oct 16;14(10):e0008270. (PMID: 33064783)
PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005162. (PMID: 28056016)
Pharmacoeconomics. 2000 May;17(5):479-500. (PMID: 10977389)
Acta Trop. 2015 Oct;150:4-13. (PMID: 26056739)
Value Health. 2016 Dec;19(8):929-935. (PMID: 27987642)
Emerg Infect Dis. 2021 Aug;27(8):2144-2153. (PMID: 34287133)
PLoS Comput Biol. 2021 Jan 29;17(1):e1008532. (PMID: 33513134)
Parasit Vectors. 2015 Oct 22;8:532. (PMID: 26490248)
Lancet Glob Health. 2017 Jan;5(1):e69-e79. (PMID: 27884709)
PLoS Negl Trop Dis. 2020 Dec 14;14(12):e0008832. (PMID: 33315896)
BMC Med. 2021 Apr 1;19(1):86. (PMID: 33794881)
PLoS Negl Trop Dis. 2015 Aug 12;9(8):e0003727. (PMID: 26267667)
Trans R Soc Trop Med Hyg. 2021 Mar 6;115(3):245-252. (PMID: 33611586)
Bull World Health Organ. 1994;72(3):429-45. (PMID: 8062401)
J Infect Dis. 2020 Feb 3;221(4):561-565. (PMID: 31565733)
Clin Infect Dis. 2018 Jun 1;66(suppl_4):S286-S292. (PMID: 29860287)
Trends Parasitol. 2018 Mar;34(3):197-207. (PMID: 29396200)
Lancet. 2017 Nov 25;390(10110):2397-2409. (PMID: 28673422)
PLoS Negl Trop Dis. 2017 Nov 13;11(11):e0006060. (PMID: 29131822)
Bull World Health Organ. 2004 Sep;82(9):683-8. (PMID: 15628206)
Wkly Epidemiol Rec. 2006 Feb 24;81(8):71-80. (PMID: 16673459)
PLoS Negl Trop Dis. 2017 Jul 27;11(7):e0005792. (PMID: 28750007)
Parasit Vectors. 2008 Feb 12;1(1):3. (PMID: 18275594)
PLoS Negl Trop Dis. 2015 Aug 12;9(8):e0003822. (PMID: 26267814)
Nat Commun. 2022 Mar 18;13(1):1448. (PMID: 35304479)
J Infect Dis. 2020 Jun 11;221(Suppl 5):S539-S545. (PMID: 31876949)
PLoS One. 2018 Sep 21;13(9):e0204335. (PMID: 30240406)
Med Decis Making. 2002 Jul-Aug;22(4):290-308. (PMID: 12150595)
PLoS Negl Trop Dis. 2020 May 21;14(5):e0008261. (PMID: 32437391)
Parasit Vectors. 2020 Aug 14;13(1):419. (PMID: 32795375)
تواريخ الأحداث: Date Created: 20220226 Date Completed: 20220412 Latest Revision: 20240824
رمز التحديث: 20240826
مُعرف محوري في PubMed: PMC8881616
DOI: 10.1038/s41467-022-28598-w
PMID: 35217656
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-022-28598-w